Summary of Key Points Group 1: Unlocking Scale and Impact - In August, 112 listed companies in A-shares will face unlocking, with a total market value of 517.205 billion yuan, significantly higher than the unlocking values of June and July, which did not exceed 290 billion yuan [1][2] - The unlocking value in August is the highest for the remaining months of the year, with September, October, November, and December estimated at approximately 284.1 billion yuan, 364.6 billion yuan, 148.3 billion yuan, and 384.2 billion yuan respectively [1] - The major contributor to the unlocking scale is Haiguang Information, with an unlocking value of 198.054 billion yuan, accounting for 38.3% of the total unlocking value for the month [1][2] Group 2: Significant Companies and Their Unlocking Values - Among the 112 companies, 50 have unlocking values exceeding 1 billion yuan, with Haiguang Information, Runze Technology, and United Imaging Medical leading the way [2] - The total unlocking value of the top seven companies, including Xugong Machinery and Dazhu CNC, exceeds 366.6 billion yuan, representing 70.88% of the total unlocking for August [2] - Xugong Machinery has the highest unlocking quantity at 3.569 billion shares, which is 30.37% of its total share capital, with a current unlocking yield of 68.7% [2][3] Group 3: High Unlocking Ratios and Their Implications - A significant number of companies have a high proportion of unlocking shares, with 35 companies having unlocking ratios exceeding 30%, and 13 companies exceeding 60% [3] - Dazhu CNC has the highest unlocking ratio at 84.39%, followed by Hualan Vaccine at 76.37% [3] - Haiguang Information's unlocking includes 1.438 billion shares, which is 61.85% of its total share capital, marking the first unlocking of original shareholders' restricted shares since its IPO [3] Group 4: Performance of Specific Stocks - Kema Technology has the highest unlocking yield at 575.5%, with a total unlocking of 86.5827 million shares valued at 4.679 billion yuan [4] - Other semiconductor companies like GeKongwei and Jiangbolong also have unlocking values exceeding 10 billion yuan, with Jiangbolong unlocking 1.55 billion shares valued at 13.6 billion yuan [4] - The unlocking of shares from strategic placement shareholders in Kema Technology includes significant holdings from companies like Zhongwei and Tuojing Technology [4] Group 5: Trends in Financing and Market Performance - Among the 18 stocks with unlocking shares from private placements, 14 have positive yields, with Runze Technology, Leshan Power, and Nanya New Materials leading with yields of 384.56%, 170.06%, and 215.27% respectively [6] - Runze Technology's stock price has increased by 114% since 2022, with a significant unlocking of 1.075 billion shares valued at 51.8 billion yuan [6] - The semiconductor sector is experiencing heightened interest, with several companies seeing substantial stock price increases due to market trends [6][7]

智通财经APP讯，联影医疗(688271.SH)发布公告，公司员工持股平台持有的公司股份为首次公开发行 前公司实施的员工股权激励，员工持股平台持有人为800余名公司员工。因部分员工提出所持员工持股 计划份额所对应的公司股份出售申请(以下简称"出售申请")，员工持股平台拟通过大宗交易或集中竞价 (含盘后固定价格交易，下同)方式合计减持联影医疗股份不超过1337.66万股，合计不超过联影医疗总股 份的1.6231%。 ...

人民财讯8月3日电，联影医疗(688271)8月3日晚间公告，因部分员工提出所持员工持股计划份额所对应 的公司股份出售申请(简称"出售申请")，员工持股平台拟通过大宗交易或集中竞价(含盘后固定价格交 易)方式合计减持联影医疗股份不超过1337.66万股，合计不超过联影医疗总股份的1.6231%。 ...

格隆汇8月3日｜联影医疗(688271.SH)公告称，公司员工持股平台宁波影聚、宁波影力、宁波影健、宁 波影康、上海影董因部分员工提出出售申请，拟通过大宗交易或集中竞价方式合计减持公司股份不超过 13,376,600股，合计不超过公司总股份的1.6231%。减持价格参考市场价格，减持期间为2025年8月25日 至2025年11月24日。 ...

上述股份系其在首次公开发行前取得的股份，已于 2023 年 8 月 22 日起上市 流通。 减持计划的主要内容 证券代码：688271 证券简称：联影医疗 公告编号：2025-030 上海联影医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海联影医疗科技股份有限公司（以下简称"公司" 或"联影医疗"）股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）（以 下简称"宁波影聚"）持有公司股份 11,145,243 股，占公司总股本的 1.35%；宁 波梅山保税港区影力投资管理合伙企业（有限合伙）（以下简称"宁波影力"）持 有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影健投 资管理合伙企业（有限合伙）（以下简称"宁波影健"）持有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影康投资管理合伙企业（有限合 伙）（以下简称"宁波影康"）持有公司股份 ...

联影医疗公告，宁波影聚、宁波影力、宁波影健、宁波影康、上海影董等员工持股平台合计持股 5458.44万股，占6.62%。因员工出售申请，计划2025年8月25日至2025年11月24日期间，通过集中竞价 减持不超过824.14万股，大宗交易减持不超过1337.66万股，合计不超过1337.66万股，占1.6231%，股份 来源为IPO前取得。 ...

融券方面，当日融券卖出0.00万股，净买入0.79万股。 来源：金融界 最近三个交易日，30日-1日，联影医疗分别获融资买入0.22亿元、0.20亿元、0.14亿元。 8月1日，沪深两融数据显示，联影医疗获融资买入额0.14亿元，居两市第950位，当日融资偿还额0.18亿 元，净卖出423.93万元。 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown positive performance, with a recent increase in its index value, indicating a growing interest and investment in the healthcare sector [1][2]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the China Securities Index for Healthcare Equipment and Services rose by 0.47%, closing at 14,515.51 points with a trading volume of 28.859 billion [1]. - Over the past month, the China Securities Index for Healthcare Equipment and Services has increased by 6.65%, by 10.76% over the last three months, and by 6.04% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include: Mindray Medical (9.14%), United Imaging (8.05%), Aier Eye Hospital (7.32%), Aimeike (3.41%), Huatai Medical (2.89%), New Industry (2.6%), Yuyue Medical (2.57%), Lepu Medical (2.52%), Yingke Medical (2.06%), and Meinian Health (2.0%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (59.97%) and the Shanghai Stock Exchange (40.03%) [1]. Group 3: Industry Focus - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare industries [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, indicating a robust interest in this sector [2].

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]